← Human Trials & Peer-Reviewed Studies
Recombinant growth hormone therapy for cystic fibrosis in children and young adults.
Plain-language guide to PMID 30557452 (2018): meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 30557452
- Journal
- The Cochrane database of systematic reviews
- Year
- 2018
- Study type
- Meta-Analysis
- Authors
- Thaker V et al. (3 authors)
- DOI
- 10.1002/14651858.CD008901.pub4
What This Paper Covers, in Plain Language
What It Covers
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this meta-analysis publication.
Cystic fibrosis (CF) is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas.
People with CF often have malnutrition and growth delay.
Who the Included Studies Covered
By PubMed's age tags, the people studied were children, teenagers and young adults.
How the Review Was Done
The researchers searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Date of latest search: 22 October 2018.the researchers also searched ongoing trials registers in clinicaltrials.gov from the United States and WHO International Clinical Trials Registry Platform (ICTRP).
Date of latest search: 05 March 2018.the researchers conducted a search of relevant endocrine journals and proceedings of the Endocrinology Society meetings using Web of Science, Scopus and Proceedings First.
Date of latest search: 04 March 2018.
What Was Measured
Two authors independently screened papers, extracted trial details and assessed their risk of bias.
The researchers assessed the quality of the evidence using the GRADE system.
The subject headings attached to it are Blood Glucose, Body Height, Body Mass Index, Cystic Fibrosis, Exercise Tolerance, Fasting and Forced Expiratory Volume.
What This Means in Plain Language
This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 16 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (The Cochrane database of systematic reviews), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.